Manufacturer record
Navkar Lifesciences WHO-GMP Certified Company: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Navkar Lifesciences WHO-GMP Certified Company (Himachal Pradesh) were declared Not of Standard Quality in August 2022. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: TF2037A, Ursodeoxycholic Acid Tablets IP 300 mg (BAKLIV-300 TABLETS) (exp May 2024). RDTL Chandigarh (CDSCO lab) found it not of standard quality: Identification A, Identification B and Assay. Listed in the August 2022 alert.
Records by type
2 records linked to Navkar Lifesciences WHO-GMP Certified Company in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Ursodeoxycholic Acid Tablets IP 300 mg (BAKLIV-300 TABLETS) | Batch TF2037AMfg Jun 2022 · Exp May 2024 | Identification A, Identification B and AssayAssay | RDTL ChandigarhCDSCO lab | Aug 2022 |
| Mefenamic Acid and Paracetamol Tablets (MEFIGESIC FORTE TABLETS) | Batch TD2030BMfg Apr 2022 · Exp Mar 2024 | Assay of Mefenamic AcidAssay | RDTL ChandigarhCDSCO lab | Aug 2022 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.